Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., has reported a decline in its financial performance for the first half of 2025, with a focus on revenue and profit reductions, while also announcing a cash dividend distribution plan for shareholders [2][4]. Financial Performance Summary - For the first half of 2025, the company's main revenue was 1.304 billion yuan, a year-on-year decrease of 7.12% [2][6]. - The net profit attributable to shareholders was 211 million yuan, down 10.29% year-on-year [2][6]. - The net profit after deducting non-recurring gains and losses was 204 million yuan, a decline of 11.35% compared to the previous year [2][6]. - In Q2 2025, the company reported a single-quarter main revenue of 686 million yuan, a decrease of 9.57% year-on-year [2][6]. - The single-quarter net profit attributable to shareholders was 121 million yuan, down 12.33% year-on-year [2][6]. - The company's debt ratio stood at 18.14%, with investment income recorded at -28,700 yuan and financial expenses at 30.89 million yuan [2][6]. - The gross profit margin was reported at 70.17% [2][6]. Company Announcements Summary - The company’s subsidiary, Haohai Biological Technology Holdings Co., Ltd., has terminated its exclusive distribution agreement with Hengtai Optical and Hengtai Vision due to Hengtai Optical's acquisition by Carl Zeiss [3]. - As part of the termination agreement, Hengtai Optical's major shareholders will pay 80 million yuan as a termination compensation [3]. - Hengtai Vision reported total assets of 11.52 million yuan, net assets of 5.06 million yuan, and an operating income of 18.85 million yuan, with a net loss of 3.65 million yuan for the first half of 2025 [3]. - The company plans to increase market promotion for its self-developed OK lens products and optimize product structure [3]. - The cash dividend distribution plan for the first half of 2025 is set at 4.00 yuan per 10 shares (including tax), totaling 91.49 million yuan, which accounts for 43.35% of the net profit attributable to shareholders [4][6].

Core Viewpoint - The announcement details a significant partnership and investment involving昊海生物科技,亨泰光学, and亨泰视觉, which includes exclusive distribution rights and equity acquisition, indicating a strategic move to enhance market presence in the optical lens sector [1][2]. Group 1: Exclusive Distribution Agreement -昊海生物科技's subsidiary,昊海控股, has signed an exclusive distribution agreement with亨泰光学 and亨泰视觉 for high-end orthokeratology contact lenses "迈儿康myOK" in mainland China for a duration of 10 years, expiring on December 31, 2030 [1]. - The agreement also grants昊海控股 exclusive distribution rights for children's myopia management optical lenses "贝视得" in mainland China [1]. Group 2: Equity Acquisition -昊海发展, another subsidiary of昊海生物科技, has entered into an investment agreement to acquire a 55% stake in亨泰视觉 for RMB 25 million, making亨泰视觉 a controlled subsidiary and included in the consolidated financial statements of the company [1]. - Following a change in control of亨泰光学 due to a proposed acquisition by Carl Zeiss Vision International GmbH,昊海控股 and亨泰光学's major shareholders have signed a termination agreement for the existing cooperation [2]. - As part of the termination agreement,亨泰光学's major shareholders will pay昊海控股 a termination compensation of RMB 80 million [2].

Core Viewpoint - The company has entered into exclusive distribution agreements and investment agreements with Hengtai Optical and Hengtai Vision, which will significantly impact its market position in the high-end contact lens sector in China [1][2]. Group 1: Exclusive Distribution Agreements - The company’s wholly-owned subsidiary, Haohai Biotechnology Holdings, signed an exclusive distribution agreement with Hengtai Optical and Hengtai Vision for the high-end orthokeratology contact lens product "myOK" in mainland China for a duration of 10 years, expiring on December 31, 2030 [1]. - The agreement also includes the exclusive distribution rights for Hengtai Vision's optical lenses for children's myopia management, named "Beishide," in mainland China [1]. Group 2: Investment Agreement - The company’s subsidiary, Haohai Pharmaceutical Technology Development, has signed an investment agreement to acquire a 55% stake in Hengtai Vision for RMB 25 million, making Hengtai Vision a subsidiary and consolidating it into the company's financial statements [1]. Group 3: Termination of Existing Cooperation - Due to Carl Zeiss Vision International's intention to acquire 100% of Hengtai Optical, the existing cooperation between Haohai Holdings and Hengtai Optical will be terminated, with a compensation payment of RMB 80 million to Haohai Holdings [2]. - Following the termination, Hengtai Vision will transfer 45% of its shares from its minority shareholder to Haohai Development, making Hengtai Vision a wholly-owned subsidiary of Haohai Development [2].